This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Sep 2014

Almac’s Clinical Supply Chain Management Service Responds to Growth in Demand for Biologics and Global Trials

As clinical studies become truly global, sponsor companies face challenges with shorter availability of complex investigational products, variable patient demands and the pressures on an increasingly stretched global supply chain. Coupled with the need for global provision of expensive comparators, sponsors are seeking oversight across all aspects of their clinical supply chain.

 

Almac has continued developing their unique supply chain management (SCM) service that blends consultancy, supportive technology and end-to-end supply chain visibility. This gives sponsors more control over the complete supply chain, driving down costs, reducing timeframes and aligning clinical supply with patient demand globally.

 

The Almac solution of single system integration of forecasting, Material Resource Planning (MRP) and Interactive Response Technology (IRT) provides data in real-time.  As a consequence, the dedicated SCM experts are able to assume responsibility to make key decisions, thereby ensuring reliable and efficient supply of clinical trial material to meet patient demand.

 

Almac’s latest service offering further enhances and supplements their core manufacturing, packaging and distribution services for investigational products and offers clients the best and most comprehensive clinical supply chain management solution available on the global marketplace.

 

Michelle Foust, Almac’s Director of Supply Chain Strategy stated: “Almac has been providing clinical SCM for more 25 years and in response to the challenges experienced by our global client base, we have developed novel solutions for use across multiple study types. Indeed, we are confident that our consultancy-based offering optimises clinical trial supply, thereby minimising waste and decreasing costs for our partners.”

Related News